首页> 外国专利> Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease

Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease

机译:建立维多珠单抗给药方案以治疗肠易激惹疾病的方法

摘要

The present invention provides methods for predicting whether an individual having inflammatory bowel disease (IBD) is likely to respond to vedolizumab treatment. Also provided are methods for predicting whether an individual with IBD such as Crohn's disease or ulcerative colitis will develop autoantibodies against vedolizumab. The present invention also provides a treatment regimen for an IBD patient which includes measuring the level of one or more predictive markers of response to vedolizumab prior to administering the anti-α4β7 integrin drug.
机译:本发明提供了用于预测患有炎性肠病(IBD)的个体是否可能对维多珠单抗治疗有反应的方法。还提供了用于预测患有诸如克罗恩氏病或溃疡性结肠炎等IBD的个体是否会发展出针对维多珠单抗的自身抗体的方法。本发明还提供了一种用于IBD患者的治疗方案,其包括在施用抗α4β7整联蛋白药物之前测量对维多珠单抗反应的一种或多种预测性标志物的水平。

著录项

  • 公开/公告号US10324088B2

    专利类型

  • 公开/公告日2019-06-18

    原文格式PDF

  • 申请/专利权人 NESTEC S.A.;

    申请/专利号US201715601921

  • 申请日2017-05-22

  • 分类号A61K39/395;A61K39;G01N33/564;G01N33/68;G01N33/15;G01N33/48;

  • 国家 US

  • 入库时间 2022-08-21 12:16:26

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号